INTRODUCTION

Antimicrobial resistance
Antimicrobial resistance especially antibacterial is not a new-found phenomenon, and it has become an increasingly serious health concern. World Health Organization (WHO) stated that antimicrobial resistance us one of the most vital public health problem. 1 Data has shown that the yearly mortality rate caused by antimicrobial resistance infections are 23 .000 in America, 25 .000 in the Europe Union, and 58.000 in India. 2 These findings have stimulated a lot of global surveillance action. 1, [3] [4] [5] Antimicrobial resistance has caused a significant delay of effective treatment course for infectious diseases, and often times even caused patients to fail to receive proper treatment. Many advancements in the medicine world, for instance, the presence of chemotherapy for cancer and organ transplantation, are very dependent on an effective anti-infection. This also has implications not only medically but also economically. In addition to that, other disadvantages that can not be counted, like chronic pain, hindrance in daily activities, and psychological costs. 6 The estimation of yearly expenses caused by antimicrobial resistance in America had reached 55 billion dollars and in Europe 1,5 billion euro, in which the 900 million euro was due to inpatient treatment and loss of productivity at work. 4, 7 General data in some countries showed that the incidence of antimicrobial resistance including multidrug resistance (MDR) both in the hospital and community settings are constantly increasing. 6 This resistance is complex and multifactorial. Nonetheless, irrational antimicrobial usage is still thought to be the most important factor. 7 Unnecessary antibacterial prescription, as well as unstandardized dosage, contributes 50% overall antimicrobial usage. 4 The lack of regulation of antimicrobial utilization in other non-medical sectors, for instance, farming, is causing this issue to become more complex. 7 The discovery of antibacterial as one kind of antimicrobial agent that can eradicate bacterial were considered a revolution of health sector during the 20th centuries. 8 The history of antibacterial agents begun in 1928, when Alexander Fleming accidentally discovered penicillin for the first time. In 1929, Fleming wrote about penicillin for the first time, however at that time penicillin was not used for medical purposes, until a team from Oxford University did so in the 1940s. 9 In the next phase, the precence of many kinds of antimicrobial agents had saved so many lives from infectious diseases, which in the pre-antibiotic era was incurable. 10 The existence of antimicrobial agents is limited and non-renewable, which human beings will always need. 10 This had been proven in 1947, only 4 years after penicillin was mass-produced, Staphylococcus aureus (S. aureus) resistance to penicillin had been reported. 8 Bacterial can develop antibacterial resistance through several mechanisms, for instance through inhibiting pathway, modifying site of action, efflux mechanism, drug-target mutation, and membrane permeabilities modification.
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Considering the importance of antibacterial agents in the treatment process and its irreplaceable role, guidelines for rational use of antibacterial was made, one of which is published by Infectious Diseases of Society of America (IDSA) and Society of Healthcare Epidemiology of America. 7 Other guidelines include those published by The Antibiotic Stewardship and Resistance Working Groups of the International Society for Chemotherapy, for the public settings and hospital settings. 12, 13 These guidelines are a form of strategical effort to optimize the effective use of antibacterial, lessen the occurrence of side effects, minimizing treatment cost, and finally preventing bacterial resistance. 7 The increase of antibacterial resistance happens not only inside hospital settings but also in the community. Some of this resistance are different depending on the region 5. In western countries, methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant enterococci (VRE), Escherichia coli and β-lactamase Klebsiella pneumonia (ESBL), and carbapenemresistant Enterobacteriaceae (CRE) are the most commonly seen. Among those antibacterialresistant bacterias, MRSA is the most common pathogen found in the hospitals in Asia. 
Methicillin-resistant S. aureus (MRSA)
Among all gram positive bacterias, S. aureus draws more public interest due to a very rapid resistance occurrence both in the hospitals and communities. The spreading of its resistant strain was also very massive. 10 This bacteria was first reported to be resistant to penicillin only 4 years after penicillin mass-production. 8 Before 1950, S. aureus had been resistant to penicillin-alternatives antibacterial like erythromycin, streptomycin, and tetracycline. In 1959, methicillin was found as an alternative for infections caused by S. aureus. However, only two years after methicillin was introduced, an occurrence of resistance was reported.
14 The high incidence of infection caused by MRSA demands penicillin-alternative medicines as treatment options, which price are far more expensive. 1 
Epidemiology
On the early reports, MRSA was still limited in hospital settings and rarely occurred in the community. The occurrence of resistantstrain was first reported in the early 1990s in Australia, and after a few years occurred in the Europe, United State, Latin America, and Asia.
14 Infections caused by MRSA are the most commonly found infection in hospital settings, attacking approximately 80.000 individuals every year, 11.000 of which are deadly. This infection usually occurs during hospital stay or not long after hospitalization. 4 In Asia, between 2004-2006, an infection caused by MRSA in hospital setting was 67,5% and in the community was 25,5%. 15 In the US, until late 1980s MRSA infections in the hospital was around 8-22%, however, this number increased by 60% in 2003. Similar findings were found in Latin America and other Asia Pacific region, where in early 2000s MRSA infection in hospital settings reached more than 50%. 14 Overall, the occurrence of MRSA infections in a various country are decreasing for around 30%, however, there are still some health service facilities with high incidence level, amounting to 50% or even 60%.
14 In contrary to the decreasing occurrence of MRSA infections inside the hospital, within the last decade, MRSA infection in the community (individuals who are not exposed to hospital settings) are increasing. The pattern of this infections is different from those in the hospital setting, including the strain of the MRSA. 4 The types of MRSA in the community have different genotypes from the resistant strain in the hospital and are still sensitive to some beta-lactam antibacterial, for instance, gentamycin, ciprofloxacin, and trimethoprimsulfamethoxazole. 14 The occurrence of multiple drug resistance (MDR) to MRSA in the community is lower than in the hospital. 15 
The Mechanism of Resistance
MRSA is resistant to almost all β-lactam antibacterial, which include group of penicillin (penicillin, dicloxacillin, nafcillin, oxacillin, all.) and cephalosporin. 16 This group of antibacterial works by inhibiting the synthesis of cell wall especially during the formation of peptidoglycan, which made the bacterial cell walls to become vulnerable and lysis easily. The β-lactam groups contribute as a pseudosubstrate that assimilates the active sides of bacterial penicillin-binding protein (PBP), thus inhibiting the cross-linking process of peptidoglycan polymer. 17 Most S. aureus resistance against β-lactam antibacterial is due to PBP changes. 18 The resistance of MRSA is believed to be caused by mec (mecA, mecB, dan mecC) gene, that code a specific protein called PBP2A as a form of PBP changes. PBP2A is an additional PBP excluding the four existing PBP (PBP 1-4) in native S. aureus. 18 The affinity of PBP2A against β-lactam antibacterial is lower than S.
aureus endogen PBP and can substitute the function of PBP. 19 The lack of inhibition against peptidoglycan cross-linking polymers would keep the bacterial cell walls intact even with the administration of β-lactam. 17 This condition will defend the survival of MRSA in a high concentration β-lactam environment.
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The mecA gene is located on the Staphylococcal cassette chromosome (SCC)mec, which is a mobile genetic element (MGE) in the Staphylococcus genus that can interchange between species. 20 The acquisition of bacterial resistance happens through excision and integration with the mediation ofspesific recombinase gene called ccrAB and/or ccrC, and after that the SCCmec would be integrated into Staphylococcus chromosome. 16 Therefore, it can be concluded that SCCmec has a substantial role in virulence coding, immune escape mechanism, and antibacterial resistance gene. 21 Figure 1. The scheme of Resistency in MRSA. 22 Currently, there are eleven types of SCCmec (type I-XI) in various countries, with different intrinsic characteristic and predomination among countries. 16 For instance, SCCmec III is the most dominant types in countries like Arab, Indonesia, Thailand, Vietnam, China, Singapore, and India, which is also a type that showed resistance against cefoxitin, cephazolin, gentamycin, erythromycin, tetracycline, clindamycin, and cotrimoxazole. 23 Since 1996, the occurrence of infections caused by MRSA has increased, and accompanied with decreasing sensitivity for vancomycin (vancomycin-intermediate S. aureus) in the Europe, Asia, and America. Furthermore, in 2002, there was also reports about vancomycinresistant S. aureus/VISA. 24 VISA was also found to be resistant to teicoplanin, an antibacterial similar to vancomycin, a glycopeptide antibacterial that inhibits the synthesis of cell wall. 25 Due to these similarities, the term glycopeptide-intermediate S. aureus/GISA is more preferred. 24 Decreasing sensitivity of S. aureus against glycopeptides antibacterial is mediated by tcaA, which is a gene whose expression would affect the sensitivity of MRSA against vancomycin and teicoplanin. When the gene expression is high, S. aureus will be more sensitive towards vancomycin and teicoplanin, and vice versa. Until now, the difference in pathogenicity and virulence of MSSA and MRSA are still poorly described. Clinical data showed that hospitalization period, mortality rate, and treatment cost is higher in MRSA infection when compared to MSSA. 20 The general comparison of clinical aspects between MRSA and MSSA can be seen in Table 1 . This table shows the clinical importance of MRSA compared to MSSA, where MRSA is significantly causing longer hospitalization period, higher mortality rate, and more expensive treatment cost. This indicates how important an effective treatment against MRSA really is so that morbidity can be reduced.
Alternative treatment for MRSA
The high resistance of MRSA against β-lactam is causing an emerging needs of second-line medicine. The alternative therapy for MRSA based on WHO standard includes linezolid (the 1970s) and daptomycin (1980s). 2 Except for these two medicines, another alternative like tigecycline, telavancin, and ceftaroline is also still being developed. 30 Vancomycin which was previously used as the drug of choice for MRSA is now being substituted due to increasing resistance. Unlike β-lactam antibacterial, the resistance of S. aureus against vancomycin and other glycopeptides antibacterials needed 40 years to develop.
14 This drug also needs a therapeutic drug monitoring (TDM) in its usage due to high nephrotoxicity. 30 Resistance against alternative antibacterial agents like linezolid and daptomycin had been reported before. Resistance against linezolid caused by RNA subunit 23S methylation due to chloramphenicol/florfenicol resistance (cfr) gene, would cause an alteration of ribosomal binding. 30 The cause of resistance to daptomycin is an enzyme called lysyl-phosphatidylglycerol (LPG) synthetase, that increases the synthesis of total LPG, a similar mechanism with resistance towards vancomycin. 14 Antibacterial that can still be used for MRSA with the decrease of sensitivity towards vancomycin, daptomycin, and linezolid, include quinupristin/dalfopristin, TMP-SMX, and telavancin, both as single drugs or combination with other antibacterial. 31 The occurrence of resistance towards alternative antibacterials for MRSA implicates the need for further development of other compounds that targets MRSA increasing occurrence. One potential compound that can be developed as antibacterial agent for MRSA is xanthone.
The potential of xanthone development as an anti-MRSA compound 1 Xanthone in vitro analysis of anti-MRSA activity
Discovering new treatment course can be done by utilizing traditional herbal medicine or its synthetic compounds. Some new antiinfection drugs that originated from the nature has been approved by the Food and Drug Administration (FDA) since 2005, for instance doripenem, tigecyclin, telavancin, retapamulin, and monobactam aztreonam. 11 Xanthone derivatives compounds are good antimicrobial candidates, due to their antibacterial, antiviral, and antifungal characteristic. Not only as an antimicrobial spectrum, xanthone is also effective as antitumor, antioxidant, antiallergy, and antiinflammatory.
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Xanthone derivatives (9H-xanthene-9-one) are a group of oxygen-containing heterocyclic compounds ( Figure 2 ). The main structure of xanthone includes a planar tricyclic frame where one pyran ring fused with the two accompanying rings thus called dibenzo-γ-pyrone. 33 Natural xanthone can be divided based on its additional binding groups, for instance, simple oxygenated xanthone, glycosylated xanthone, prenylated xanthone, and so on. 34 Figure 2.The main structure of xanthone 33 As an antibacterial, xanthone is effective against a lot of gram positive and gram negative bacterias. Xanthone-sensitive gram positive bacterial include Staphylococcus, Peptostreptococcus, and Streptococcus. Xanthonesensitive gram negative bacterial include Escherichia coli and Pseudomonas aeruginosa 34. Some studies showed that xanthone is not only effective against Staphylococcus aureus, but also potential against MRSA. Natural in vitro activity of xanthone against MRSA is summarized in Table 2 . Table 2 shows that the anti-MRSA activities of xanthone are different among plants in Garcinia genus. The best activities are found in α-mangostin compound (Figure 3 ) from Garcinia mangostana with MIC less than 2 µg/ mL. While the lowest activity was found in Garcinia staudtii with MIC more than 15 µg/ mL. Anti-MRSA activities of natural xanthone depend on its binding functional group. Some functional group that contributes in anti-MRSA properties of xanthone include methoxy in C-7 and hydroxy in C-5 as in Figure 4 ; H-5, 6-OH, prenyl C-8, as well as dimethyl chromene ring in C-2 and C-3 as seen in Figure 5 ; free prenyl in C-4 and hidroxy in C-5 and C-7 as seen in Figure  6 ; isoprenyl as seen in Figure 7(40) . 35, 36, 40, 42 The elimination of isoprenyl group can eliminate anti-MRSA activity. Not only that it has high anti-MRSA activity, α-mangostin from G. mangostana (AM-0016) also has much lower hemolytic activity (membranolytic) in rabbit's eritrocytes thus it is not toxic to normal tissue. 37 The results from quantitative structure-activity relationship analysis of some modified α-mangostin group show that the substitution of N-ethyl group produces better inhibitory activity (MIC 0,39-3,125 µg/mL), while longer natural N-propyl or alkylamin substitution produce lesser anti MRSA activity, with MIC ≥ 12,5 µg/mL (Table 3 ).
The order of anti-MRSA activity and hemolytic is non isoprenyl or non hydrogenized compounds< hydrogenized isoprenyl < isoprenyl. This research found that isoprenyl groups has more contribution on anti-MRSA activity, as well as affecting the hemolytic properties. 
The antibacterial mechanism of xanthone compounds against MRSA
The antibacterial mechanism of xanthone derivatives against MRSA is currently still unclear. One of the posibility of its target mechanism is through bacterial cytoplasmic membrane.
α-mangostin induces potential membrane disipation teice faster in two times Minimum Inhibitory Concentration (MIC), and thus causing a leakage of bacterial intracellular components. 37 Amphiphilic xanthone compound can disrupt bacterial membrane through a mechanism called interfacial activity model. 11 This mechanism depends on a balance between hidrophobik and electrostatic interaction of peptides, water, and lipid, and is also the basic mechanism of antimicrobial peptide/AMP. 44 Model interfacial activity contributes in the development of new AMP antibacterial agents, especially for bacterias who has been resistant. Most AMP works by damaging bacterial cell membrane so that bacterias are more prone to antibacterial agents. 45 This is why the utilization of xanthone is combined with other antibacterials that has been proven effective against MRSA and are sinergistic in nature. 39 Xanthone is also presumed to work as anti-MRSA by inducing the release of lipotheicolic acid (LTA) from MRSA cell wall. LTA is the main compound in the cell wall of Gram positive bacterias that bind convalently with the outer part of peptidoglikan which is important in cell protection. 46 The damage of LTA will ease the work of other antibacterial agents to eradicate target bacterias. Xanthone ability as an antioxidant is also presumed to contribute to its role against MRSA. 47 An antioxidant compounds are able to interact with the cell membrane of targeted microorganism, through its ability to bind with extracellular protein, soluble protein, and bacterial cell wall. MRSA as a Gram positive bacteria will be easier to eradicate by antioxidant compound because it only has one layer cell wall, while Gram negative bacteria has more layers of cell walls. 48 Nonetheless, mamalian cell walls can also be affected by antioxidant, thus an anlysis of Xanthone's possible toxicity in normal cells is needed, for instance in erythrocyte.
All the mechanisms mentioned above leads to bacterial cell wall and membrane damage, which highly depends on Xanthone ability to penetrate the cell wall. Thus,currently, the development of xanthone as anti MRSA is more directed to design and development of smaller molecules Table 3 . α-mangostin compound from G. mangostana and its selectivity with higher membran selectivity to lessen the toxicity against normal mamalian cells. 49 Some efforts that has already been done is adding a lipophylic functional groups, like those in xanthone amphiphilic compound, which produce higher anti MRSA activity with lower membrane selectivity and lower toxicity.
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CONCLUSION
The development of MRSA in hospitals and community settings, as well as the emergence of resistancu against currently used anti MRSA antibacterials (linezolid and daptomycin) triggers continuous new research on possible anti MRSA, including xanthone. Various in vitro studies showed the ability of xanthone derivates to inhibit the growth of MRSA and its selective antibacterial nature (non-toxic to normal cells). The mechanism of action of xanthone derivates as anti-MRSA is still unclear, but it is presumed to involve bacterial cytoplasmic damage and through antioxidant activity. By discovering the structures that contributes in antibacterial activities of xanthone derivates, further xanthone development as antibacterial is possible by modifying those structures, for instance, by adding a lipophylic functional groups .
